Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye.
Location: United States, California, Irvine
Employees: 11-50
Total raised: $60M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Visionary ... | visionaryv... |
| - | Aperture V... | aperturevp... |
| - | Frazier Li... | frazierls.... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.01.2020 | Series B | $60M | - |
Mentions in press and media 14
| Date | Title | Description |
| 06.08.2025 | Named 'Great Place to Work,' Moon Rabbit Reports Record Growth, New Clients, Industry Accolades | Moon Rabbit Independent agency forges key industry partnerships, hires 28 new employees to fuel expansion NEW YORK, Aug. 6, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and health... |
| 01.08.2025 | Frazier Life Sciences: $1.3 Billion Venture Fund Closed | Frazier Life Sciences (FLS), an investment firm focused on innovative therapeutics, announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong s... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 19.02.2025 | Moon Rabbit Wraps 2024 with Key Executive Hires, New NYC Headquarters, Major Client Wins | Healthcare agency also won Fierce Pharma's 'Best New Brand Launch' award, opened London office, instituted workplace enhancements for expanding team NEW YORK, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and m... |
| 15.03.2024 | This Chewable Tablet Can Protect Humans From Lyme Disease Brought by Ticks | Joseph Henry, Tech Times 15 March 2024, 01:03 pm If you're a dog or cat owner, you know they are not ticks-free. If you're unaware, a disease can carry over humans through these parasites. While there are medications for Lyme disease, the s... |
| 05.03.2024 | Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis | - |
| 10.08.2023 | Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements | XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed enrollment of Galatea, a Phase 2a trial eval... |
| 02.02.2022 | Tarsus Pharmaceuticals, Inc. Secures $175 Million Credit Facility | Tarsus Pharmaceuticals, Inc. executed a $175 million credit facility with Hercules Capital, Inc. and Silicon Valley Bank. Availability under this credit facility potentially extends cash runway well into the anticipated commercialization of... |
| 21.06.2021 | TARSUS PHARMACEUTICALS, INC. Tarsus Pharmaceuticals : Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis (Form 8-K) | Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, cli... |
| 24.05.2021 | TARSUS PHARMACEUTICALS, INC. Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference | IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolution... |
Show more